Livagen

1. Overview

Livagen is a synthetic tetrapeptide with the amino acid sequence Lys-Glu-Asp-Ala (KEDA) and a molecular weight of 461.47 g/mol (C18H31N5O9). It was developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology as part of a broader program to create synthetic analogs of peptides isolated from organ-specific tissue extracts [8]. Livagen was derived from liver tissue extracts and is classified as a liver bioregulator peptide within the Khavinson peptide framework [5].

The peptide's name reflects its hepatic origin, and it shares the first two amino acids (Lys-Glu) with the dipeptide Vilon (KE), which was separately isolated from thymus extracts and developed as an immunomodulatory bioregulator [12]. While Vilon (KE) is a dipeptide with primarily immunoprotective properties, Livagen (KEDA) is a tetrapeptide with broader hepatoprotective and chromatin-modulating activities [5][7]. Both are components of the LIVPROTECT complex, a commercial peptide preparation marketed for liver support [14].

Livagen's most distinctive property is its ability to induce chromatin decondensation in lymphocytes from elderly individuals, reactivating ribosomal genes and releasing genes that have been silenced by age-related heterochromatinization [1][2][3]. Additionally, it inhibits enkephalin-degrading enzymes in human serum at concentrations more potent than several established peptidase inhibitors [4]. The peptide has also demonstrated hepatoprotective and immunoprotective effects in animal models of hepatitis and liver fibrosis [5].

All published research on Livagen originates from Khavinson's group and collaborating institutions in Russia and Georgia. No independent replication by Western laboratories has been published, and no human clinical trials are registered on ClinicalTrials.gov or any other international trial registry.

Sequence

Lys-Glu-Asp-Ala (KEDA)

Molecular Formula

C18H31N5O9

Molecular Weight

461.47 g/mol

CAS Number

402856-42-2

Type

Synthetic tetrapeptide (Khavinson liver bioregulator)

Source

Synthetic analog of peptide isolated from liver tissue extracts

Mechanism

Chromatin decondensation; ribosomal gene reactivation; enkephalin-degrading enzyme inhibition; epigenetic regulation

Routes Studied

In vitro (cell cultures); in vivo (animal models)

FDA Status

Not approved; no clinical trials registered

Related Peptides

Vilon (KE dipeptide), Epithalon (AEDG), Ovagen (EDL)

2. Mechanism of Action

Livagen operates through several molecular mechanisms, with the strongest evidence supporting chromatin remodeling, enzymatic inhibition of enkephalinases, and epigenetic regulation of gene expression.

Chromatin Decondensation and Gene Reactivation

The most extensively characterized mechanism of Livagen is its effect on chromatin structure in cells from elderly individuals. With aging, euchromatic regions of chromosomes undergo progressive condensation (heterochromatinization), silencing genes that were previously active in younger cells. Ribosomal genes, located at nucleolus organizer regions, are particularly affected by this age-related condensation, leading to decreased protein synthesis capacity [1][2][3].

In a landmark 2003 study, Khavinson et al. demonstrated that Livagen induced activation of ribosomal genes in lymphocytes from people aged 75-88 years through de-heterochromatinization of nucleolus organizer regions [1]. The peptide also caused decondensation of pericentromeric structural heterochromatin of chromosomes 1 and 9, and released genes that had been repressed by age-related condensation of euchromatic regions [1][2].

A 2004 comparative study examined five Khavinson peptides (Vilon, Epithalon, Livagen, Prostamax, and Cortagen) in leukocytes from subjects aged 75-88 years [2]. All five peptides induced activation of ribosome genes and decondensation of densely packed chromatin fibrils. However, Livagen and Epithalon were distinguished by their additional ability to induce deheterochromatinization of pericentromeric structural heterochromatin of chromosomes 1 and 9 -- an effect not shared by all the peptides tested [2].

Histone and DNA Interaction

The proposed mechanism for Livagen's chromatin effects involves direct interaction with histone proteins and DNA sequences. Short peptides of 2-7 amino acids have been demonstrated to penetrate cell nuclei and interact with both single- and double-stranded DNA, as well as with histone proteins H1, H2b, H3, and H4 [6][11]. The KE dipeptide sequence (shared by the first two residues of Livagen) demonstrates selective binding to TCGA DNA sequence motifs in gene promoter regions [6].

Fluorescence-labeled short peptides have been shown to penetrate into the nucleus in HeLa cells and interact specifically with deoxyribooligonucleotides and DNA in vitro [11]. These interactions are proposed to modulate chromatin conformation, making specific gene regions more accessible for transcription [6][9].

Enkephalin-Degrading Enzyme Inhibition

A distinct pharmacological activity of Livagen is its inhibition of enkephalin-degrading enzymes in human serum [4]. Enkephalins are endogenous opioid pentapeptides involved in pain modulation, and their biological activity is limited by rapid enzymatic degradation. Livagen inhibited these degrading enzymes with an IC50 of approximately 20 uM, demonstrating greater potency than established peptidase inhibitors including puromycin, leupeptin, and D-PAM [4]. Importantly, Livagen did not bind to mu or delta opioid receptors, indicating that it preserves endogenous analgesic signaling by preventing enkephalin breakdown rather than by directly activating opioid pathways [4].

Hepatoprotective Mechanisms

In animal models of liver pathology (including experimentally induced hepatitis and liver fibrosis), Livagen normalized immune and antioxidant status and restored liver function [5]. The hepatoprotective effect was particularly pronounced in aging animals, suggesting that Livagen may counteract age-related decline in liver regenerative capacity [5]. These effects are consistent with the broader Khavinson bioregulator theory, which proposes that organ-specific short peptides restore age-related functional decline in their tissues of origin [8][10].

3. Researched Applications

Chromatin Reactivation in Aging

Evidence level: In vitro (human lymphocytes)

The primary researched application of Livagen is the reversal of age-related chromatin condensation. Three independent studies from Khavinson's group and Georgian collaborators have demonstrated that Livagen reactivates ribosomal genes and decondenses heterochromatin in lymphocytes from elderly subjects [1][2][3]. This effect has potential implications for age-related immunosenescence, as decreased ribosomal gene activity limits the protein synthesis capacity of immune cells, potentially contributing to the decline in immune function observed with aging [3][12].

Hepatoprotection and Liver Regeneration

Evidence level: Preclinical (animal studies)

A 2020 review by Kuznik, Khavinson, and Linkova comprehensively evaluated the hepatoprotective properties of both the liver polypeptide complex (Ventvil, the crude extract from which Livagen was derived) and the KEDA tetrapeptide itself [5]. In experimental models of liver fibrosis, acute hepatitis, and chronic hepatitis in animals, both preparations demonstrated high efficacy in restoring liver function [5]. The maximum hepatoprotective and immunoprotective effects were observed in aging animals, consistent with the bioregulator theory that these peptides primarily restore age-depleted signaling [5].

Endogenous Pain Modulation

Evidence level: In vitro (enzyme assay)

Livagen's inhibition of enkephalin-degrading enzymes suggests a potential application in pain modulation through preservation of endogenous opioid peptides [4]. Unlike conventional opioid analgesics, which directly activate opioid receptors and carry risks of dependence and respiratory depression, Livagen's mechanism would enhance the body's own analgesic capacity without direct receptor activation [4]. This remains a theoretical application with no in vivo validation published.

Epigenetic Anti-Aging

Evidence level: In vitro

The 2023 study on epigenetic modification of aged chromatin by peptide bioregulators further supports the concept that Livagen and related peptides can reverse age-associated epigenetic changes [9]. By restoring chromatin to a more open, transcriptionally active state, these peptides may counteract the progressive gene silencing that characterizes cellular aging [9][7].

4. Clinical Evidence Summary

5. Dosing in Research

No standardized human dosing has been established for Livagen. All dosing data come from in vitro studies and animal experiments. The following table summarizes research doses used in published studies.

In the anti-aging and peptide bioregulation community, Livagen is sometimes marketed in capsule form (typically 20 capsules containing 200 ug each) or as a lyophilized powder for reconstitution. These commercial formulations have not been validated in controlled human studies, and their bioavailability and efficacy are uncharacterized.

6. Livagen vs. Vilon (KE Dipeptide)

Livagen (KEDA) and Vilon (KE) are closely related peptides within the Khavinson bioregulator family that share the Lys-Glu (KE) sequence but differ in length and primary target tissue.

Vilon (KE) is a dipeptide (Lys-Glu) with a molecular weight of 275.30 g/mol. It was isolated from thymus extracts and is classified as a thymic bioregulator. Vilon demonstrates primarily immunoprotective, geroprotective, and oncostatic activities, and stimulates functional activity of fibroblasts [7][12]. It activates chromatin in elderly lymphocytes through similar mechanisms to Livagen but does not induce pericentromeric heterochromatin decondensation of chromosomes 1 and 9 [2][3].

Livagen (KEDA) is a tetrapeptide (Lys-Glu-Asp-Ala) with a molecular weight of 461.47 g/mol. It was derived from liver tissue extracts and demonstrates both the immunomodulatory properties shared with Vilon and additional hepatoprotective activities [5]. Livagen induces a broader spectrum of chromatin changes, including the pericentromeric decondensation effect unique to Livagen and Epithalon among the tested bioregulators [2].

The two peptides are often used in combination in the commercial LIVPROTECT complex, suggesting complementary rather than redundant mechanisms of action [14].

7. Safety and Side Effects

Published Safety Data

No systematic toxicology studies meeting international regulatory standards have been published for Livagen. The available safety information is limited to observations from in vitro experiments and animal studies:

• In vitro studies in human lymphocyte cultures reported no cytotoxic effects at the concentrations tested [1][2][3]
• Animal studies of the liver polypeptide complex and KEDA peptide in models of hepatitis and fibrosis did not report treatment-related adverse effects [5]
• The lack of opioid receptor binding suggests that Livagen's enkephalinase inhibition would not produce opioid-type side effects such as respiratory depression, sedation, or dependence [4]

Safety Gaps

Significant safety gaps remain:

• No formal dose-escalation or maximum tolerated dose studies in any species
• No reproductive or developmental toxicity studies
• No drug interaction studies
• No pharmacokinetic studies defining absorption, distribution, metabolism, or elimination
• No long-term administration studies
• No independent safety assessment by laboratories outside the Khavinson research network
• The effects of sustained chromatin decondensation on genomic stability have not been evaluated

8. Regulatory Status

Livagen is not approved by the FDA, EMA, or any major Western regulatory agency for therapeutic use. No clinical trials are registered on ClinicalTrials.gov. It is available from research chemical suppliers and as a dietary supplement component in some jurisdictions, but it is not a licensed pharmaceutical product outside of Russia. In Russia, the liver polypeptide complex (Ventvil) from which Livagen was derived has been used in clinical settings, but the synthetic KEDA tetrapeptide itself does not hold separate pharmaceutical registration.

9. Pharmacokinetics

No formal pharmacokinetic studies have been published for Livagen (KEDA). The available pharmacokinetic understanding is limited to indirect inferences from the in vitro IC50 data and general peptide metabolism principles.

The enkephalin-degrading enzyme inhibition study provides the only quantitative pharmacological parameter: IC50 of approximately 20 uM [4]. This concentration represents the plasma or tissue level needed for 50% enzyme inhibition, providing a target exposure for pharmacokinetic modeling. However, whether this concentration is achievable in vivo following any route of administration is unknown.

As a tetrapeptide of 461 g/mol, KEDA faces rapid proteolytic degradation in plasma and tissues. The lysine residue at the N-terminus is readily cleaved by aminopeptidases, and the alanine at the C-terminus is susceptible to carboxypeptidases. No plasma half-life, oral bioavailability, or tissue distribution data have been published.

The commercially available capsule formulation (200 ug per capsule) would need to survive gastrointestinal degradation and achieve systemic absorption to reach target tissues (liver, immune cells). No data support the achievability of biologically active concentrations following oral dosing. The hepatic first-pass effect is particularly relevant for a liver-targeted peptide, as any absorbed peptide would encounter high concentrations of hepatic peptidases during first-pass metabolism.

10. Dose-Response

No dose-response studies have been conducted for Livagen in any system. The chromatin decondensation studies applied Livagen to lymphocyte cultures at experimental concentrations without dose titration [1][2][3]. The enzyme inhibition study provided an IC50 (approximately 20 uM) [4], which is the closest approximation to dose-response data, but this was measured in a cell-free enzyme assay rather than in living cells or organisms.

The hepatoprotective animal studies used course-based treatment without dose-response comparison [5]. The commercially available formulations suggest 200 ug per capsule, but this dose has no pharmacological optimization behind it -- it follows the standard Khavinson bioregulator convention.

The enkephalinase inhibition IC50 of 20 uM translates to approximately 9.2 ug/mL in plasma. Achieving this concentration systemically from a 200 ug oral dose would require near-complete absorption and negligible distribution -- a pharmacokinetically implausible scenario for an unmodified tetrapeptide.

11. Comparative Effectiveness

Livagen (KEDA) vs. Epithalon (AEDG)

Both are tetrapeptide chromatin remodeling agents that induce deheterochromatinization of pericentromeric structural heterochromatin of chromosomes 1 and 9 in aged lymphocytes [2]. This shared chromatin effect distinguishes them from Vilon, Prostamax, and Cortagen, which lack the chromosome 1/9 pericentromeric specificity. Epithalon has a substantially larger research base, including telomerase activation, primate studies, and limited human data. Livagen's unique properties include enkephalinase inhibition [4] and hepatoprotective activity [5], which Epithalon does not share.

Livagen (KEDA) vs. Ovagen (EDL)

Both are liver-targeted peptides in the Khavinson system. Livagen is a tetrapeptide with demonstrated chromatin effects and enkephalinase inhibition; Ovagen is a tripeptide with documented Ki-67 upregulation and p53 suppression in aged liver tissue. They are proposed to have complementary rather than redundant mechanisms. No head-to-head comparison exists.

Livagen vs. Conventional Hepatoprotective Agents

Established hepatoprotective agents include silymarin (milk thistle), N-acetylcysteine, ursodeoxycholic acid, and S-adenosylmethionine, all with defined mechanisms and varying levels of clinical evidence. Livagen's hepatoprotective mechanism (gene regulation via chromatin remodeling) is fundamentally different and lacks comparative efficacy data against any of these agents.

12. Enhanced Safety

No adverse effects have been reported in any Livagen study [1][2][3][5]. In vitro studies showed no cytotoxicity in lymphocyte cultures [1][2][3]. The animal hepatitis/fibrosis studies did not report treatment-related adverse effects [5].

The lack of opioid receptor binding [4] is an important safety feature, distinguishing Livagen from opioid analgesics. Its enkephalinase inhibition preserves endogenous opioid signaling without directly activating opioid pathways, eliminating risks of respiratory depression, sedation, or dependence that characterize conventional opioid medications.

The sustained chromatin decondensation effect raises theoretical genomic stability concerns. Pericentromeric heterochromatin plays a role in chromosome segregation during cell division, and its persistent decondensation could theoretically increase chromosomal instability or aneuploidy risk. This concern has not been addressed in published studies.

No formal toxicology studies, reproductive toxicity assessments, drug interaction studies, or long-term safety evaluations have been conducted. All safety data originate from the Khavinson research network. The commercial LIVPROTECT combination (Livagen plus Vilon) introduces additional interaction variables between the two peptides that have not been characterized for safety.

13. Related Peptides

See also: Epithalon, Thymalin, Ovagen, Pancragen

14. References

1. [1] Khavinson VKh, Lezhava TA, Malinin VV. (2003). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bulletin of Experimental Biology and Medicine. DOI PubMed
2. [2] Khavinson VKh, Lezhava TA, Monaselidze JR, Jokhadze TA, Dvalishvili NA, Bablishvili NK, Trofimova SV. (2004). Effects of short peptides on lymphocyte chromatin in senile subjects. Bulletin of Experimental Biology and Medicine. DOI PubMed
3. [3] Lezhava TA, Monaselidze JR, Kadzhaia MV, Jokhadze TA, Khavinson VKh. (2006). Anti-aging peptide bioregulators induce reactivation of chromatin. Georgian Medical News. PubMed
4. [4] Khavinson VKh, Tendler SM, Kasyanenko NA, Lezhava TA. (2003). Effects of Livagen and Epitalon, new peptide bioregulators, on enkephalin-degrading enzymes from human serum. Biology Bulletin. DOI PubMed
5. [5] Kuznik BI, Khavinson VKh, Linkova NS. (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology. Advances in Gerontology. PubMed
6. [6] Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
7. [7] Khavinson VKh, Linkova NS, Diatlova AS, Trofimova SV. (2020). Peptide regulation of cell differentiation. Stem Cell Reviews and Reports. DOI PubMed
8. [8] Khavinson VKh. (2002). Peptides and ageing. Neuro Endocrinology Letters. PubMed
9. [9] Khavinson VKh, Lezhava TA. (2023). Epigenetic modification under the influence of peptide bioregulators on old chromatin. Advances in Gerontology. PubMed
10. [10] Anisimov VN, Khavinson VKh. (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
11. [11] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
12. [12] Lezhava TA, Jokhadze TA, Monaselidze JR, Khavinson VKh. (2004). Bioregulator Vilon-induced reactivation of chromatin in cultured lymphocytes from old people. Biogerontology. PubMed
13. [13] Morozov VG, Khavinson VKh. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology. DOI PubMed
14. [14] Khavinson VKh. (2020). Peptide medicines: past, present, future. Klinicheskaia Meditsina (Mosk).
15. [15] Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
16. [16] Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Korf HW. (2012). Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture. Bulletin of Experimental Biology and Medicine. DOI PubMed
17. [17] Khavinson VKh, Kuznik BI, Ryzhak GA. (2012). Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. DOI PubMed
18. [18] Khavinson VKh, Malinin VV. (2005). Gerontological aspects of genome peptide regulation. Karger Publishers.